LEAH ROGERS: Open Payments
NPI 1982965224 · WARSAW, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$352 in 20 payments from 11 companies in 2025. Trend: 2023 $271 · 2024 $439 · 2025 $352
Food & beverage: $352
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $63 |
| Merck Sharp & Dohme LLC | 3 | $53 |
| ABBVIE INC. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Exact Sciences Corporation | 1 | $15 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Veozah, Dexcom G6 Transmitter, LEQVIO, M-M-R II, ENFLONSIA.
Industry payments across MO — which companies pay providers there.
